PATENT CLAIM ANALYSIS

Application Number: 16060868
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["424", "400000"]

Abstract:
The present invention relates to a formulation comprising a primary surfactant, a tocol phosphate, water, an active agent, and optionally an oil, wherein the active agent and/or the optional oil comprises a hydrophobic phase.

Claim (Index 30):
The formulation of  claim 18  wherein the active agent is selected from the group consisting of amprenavir, bexarotene, calcitriol, clofazimine, cyclosporine (or cyclosporin), digoxin, doxercalciferol, dronabinol, dutasteride, etoposide, isotretinoin, itraconazole, lopinavir, ritonavir, loratadine, nifedipine, nimodipine, phenobarbital, progesterone, risperidone, saquinavir, sirolimus, tretinoin, valproic acid, amiodarone HCl, chlordiazepoxide HCl, diazepam, dihydroergotamine mesylate, fenoldopam, oxytetracycline, paricalcitrol, pentobarbital sodium, phenytoin sodium, phytonadione, propofol, ziprasidone mesylate, docetaxel, etoposide, fulvestrant, haloperidol decanoate, leuprolide acetate, viadur, lorazepam, paclitaxel, tacrolimus, teniposide, testosterone enanthate, testosterone cypionate, estradiol cypionate and valrubicin.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13740091', '13272432', '13272427', '12778591', '13042221']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7710814206421456
- 35 USC 102 Novelty (BERT): 0.4742001648587825
- Combined Prediction Score: 0.7413932950638092
- Mean Citation Score: 145.07261200000005
- Max Citation Score: 147.47348
- Similarity Product: 117.6222415437865

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test